Our study showed the remarkable efficacy of SKB264 in the nonclinical TROP2-expressing xenograft models, with an acceptable safety profile and an excellent therapeutic window in animal studies, suggesting that SKB264 treatment may be a promising therapeutic therapy for treating gastric carcinoma and breast cancer in the clinical setting. The gene discussed is TACSTD2; the disease is breast carcinoma.